A solvent result needs context.
Read beyond the word “pass.”

What is a residual solvent result?

Residual solvents are organic volatile chemicals that can remain from manufacturing or purification. ICH Q3C(R9) discusses them for pharmaceutical substances, excipients and products. Read ICH Q3C(R9), introduction and scope (PDF). This pharmaceutical reference helps explain terminology; it does not establish that our catalogue materials are approved medicines, certified APIs or compliant with that guideline.

For a peptide purchase, start with the specific question in your brief. A result for a named solvent answers that question on the report's stated basis. It does not establish a peptide's complete identity or measured content. Keep those separate records together through the COA checklist and purity versus content guide.

Which solvents were assessed, and why?

Ask for the named analytes: the individual chemicals the analysis addressed. A document headed “residual solvents” is easier to review when it lists its scope instead of leaving you to guess what a broad heading includes.

Within its pharmaceutical scope, Q3C links testing to solvents used or produced during manufacture or purification. See Q3C section 2 (PDF). For your enquiry, ask the supplier to explain how the proposed panel relates to the particular material and available process information. Do not assume a generic panel covers every possible solvent.

For BPC-157, Semax or GHK-Cu, retain the exact material name, proposed lot and document reference. The name alone does not identify a manufacturing process or establish which solvents are present. Record any unanswered scope question before treating two offers as equivalent.

Keep these fields on one review sheet.

Keep the original report attached to the sheet. A copied number without its qualifications is a weaker record than the issued document. Use the batch-traceability guide when lot and sample identifiers need connecting.

GC is a method family, not the whole specification.

Q3C describes gas chromatography as a typical technique for residual solvents. Its R9 analytical-procedure section also highlights solvent volatility when considering validation. Read Q3C section 3.4 (PDF).

A purchasing reviewer can request the procedure reference, revision and evidence relevant to the reported analytes and sample. A heading that says “GC” does not answer all of those questions. Ask the issuing laboratory or supplier to clarify the scope rather than designing an analysis yourself.

The analytical method review guide explains the broader distinction between evidence about a procedure and checks for an individual run. An HPLC area-purity figure is a separate reported measurement; do not substitute it for the requested solvent result.

“Not detected” needs a reporting limit.

ICH Q2(R2) distinguishes the detection limit from the quantitation limit. Detection concerns identifying an analyte at a low level; quantitation concerns measuring it with suitable accuracy and precision. See the Q2 glossary and lower-range discussion (PDF).

If a report uses ND, “less than” or “below QL,” ask the issuer what the notation means for that analyte and method. Preserve the relevant limit, units and qualifier together. “Not detected” should not be rewritten as zero or as a guarantee that no trace exists.

Also keep a blank field separate from a qualified result. A blank may mean the item was not reported; ask before recording it as tested. Two qualified entries are not directly comparable until your reviewer understands their definitions and reporting limits.

A clearer report does not automatically mean a better batch.

One quotation includes a solvent entry marked ND with no notation key. A second quotation includes a qualified result, the relevant reporting limit and a sample reference. The second document provides more context for review; that alone does not establish that its material has less solvent.

Request the missing definitions from the first supplier, then compare each result against the same agreed requirement and reporting basis. Do not rank the offers by the appearance of the qualifier alone. Record which questions remain open and who will review the answers.

Keep the units exactly as reported until any conversion is checked on a consistent basis. A powder result and a liquid result may use different reporting conventions; the unit name by itself may not explain the full comparison.

Keep the tested stage visible for vials and kits.

Ask whether the report concerns bulk material, a filled unit or another identified sample. Connect that stage to the proposed order. A bulk-material report should not silently become a statement that every component of a finished pen-style kit was tested.

For GLOW or KLOW enquiries, confirm the component identities and which material the proposed report covers. Unresolved component amounts and blend totals remain questions to settle; this guide adds no formula or testing guarantee.

Separate a residual solvent question from an unexpected-result investigation. If a reported value misses an agreed criterion, use the supplier investigation guide to structure the follow-up. The document review and purchasing decision each need a clear record.

Build the documentation brief before order acceptance.

Send the peptide name, required quantity, proposed presentation and destination in the USA, Canada or Australia. State the residual solvent information your reviewer needs, including the panel, reporting basis and any agreed criteria. Ask which records are available and whether separate analysis needs to be discussed; no analysis is implied by sending an enquiry.

Wholesale Lab Peptides has warehouses in the USA, Canada, Australia and Hong Kong. Confirm current local availability and dispatch for the selected order. Amounts, pack contents and vial or defined pen-style kit configurations are confirmed during enquiry. Browse the catalogue, discuss OEM and private label supply or email sales@wholesalelabpeptides.com.